This post was originally published on this site
https://i-invdn-com.investing.com/news/fa8a2f803ea2ddf92359d55091dcde0a_M.jpg
The company’s business EPS, a measure preferred by Sanofi, is projected to experience a decline of between 8.5% and 9.5%. This estimate follows a modest growth in its business EPS reported in the second quarter of this year, which saw an increase of 0.6% on a reported basis and 8.1% when adjusted for constant exchange rates.
Alongside the projected impact on the business EPS, Sanofi also foresees that its quarterly sales will be negatively affected by currency volatility. The company estimates a decrease of between 7.5% and 8.5% in quarterly sales due to these currency shifts.
Earlier in July, Sanofi had projected that its full-year business EPS would be reduced by between 6.5% and 7.5% due to the impact of currency movements. However, this recent update suggests that the effects of currency fluctuations on the company’s financial performance may be more significant than initially anticipated.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
